206
- Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, et al. Negative screening does
not rule out the risk of tuberculosis TB in patients with inflammatory bowel disease in IBD
patients undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohns
Colitis. 2016;10(10):1179–85. - Tuberculosis: Treatment. Centers for Disease Control and Prevention. 2016. Cited 1 July
2016. Available from: http://www.cdc.gov/tb/topic/treatment/ - Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating
tumor necrosis factor α blockade therapy. Mayo Clin Proc. 2008;83:181–94. - Huber W, Herrmann G, Schuster T, Phillip V, Saugel B, Schultheiss C, et al. Life-threatening
complications of Crohn’s disease and ulcerative colitis: a systematic analysis of admissions
to an ICU during 18 years. Dtsch Med Wochenschr. 2010;135:668–74. - Dave M, Purohit T, Razonable R, Loftus EVJ. Opportunistic infections due to inflammatory
bowel disease therapy. Inflamm Bowel Dis. 2014;20:196–212. - Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with
Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5:283–7. - Tschudy J, Michail S. Disseminated histoplasmosis and pneumocystis pneumonia in a child
with Crohn disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2010;51:221–2. - Zahr AA, Aldin ES, Yunyongying P. Histoplasma epiglottitis in a patient with Crohn’s disease
maintained on infliximab, prednisone, and azathioprine. Int J Infect Dis. 2013;17:e650–2. - Pinheiro Bdo V, Delgado Ade A, Chebli J. Hepatitis and pneumonitis during adalimumab
therapy in Crohn disease: mind the histoplasmosis! Arq Gastroenterol. 2014;51:73–6. - Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, et al. Histoplasmosis
after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med.
2003;167:1279–82. - Jain V, Evans T, Peterson M. Reactivation histoplasmosis after treatment with anti-tumor
necrosis factor alpha in a patient from a nonendemic area. Respir Med. 2006;100:1291–3. - Lim LT, Ruzmetova N, Ballinger SH, Moorthy RS. Acute pulmonary histoplasmosis in a
patient with uveitis after infliximab therapy. Int Ophthalmol. 2011;31:349–51. - Dotson JL, Crandall W, Mousa H, Honegger JR, Denson L, Samson C, et al. Presentation
and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with
antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17:56–61. - Taroumian S, Knowles SL, Lisse JR, Yanes J, Ampel NM, Vaz A, et al. Management of
coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying
antirheumatic drugs. Arthritis Care Res. 2012;64:1903–9. - Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of
coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis
Rheum. 2004;50:1959–66. - De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pul-
monary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-
neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol.
2003;24:477–82. - Alderson JW, Van Dinter TGJ, Opatowsky MJ, Burton EC. Disseminated aspergillosis fol-
lowing infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic
hepatitis C: a case study and review of the literature. MedGenMed. 2005;7:7. - Manz M, Beglinger C, Vavricka S. Fatal invasive pulmonary aspergillosis associated with
adalimumab therapy. Gut. 2009;58:149. - Osawa R, Singh N. Colitis as a manifestation of infliximab-associated disseminated crypto-
coccosis. Int J Infect Dis. 2010;14:e436–40. - Fraison JB, Guilpain P, Schiffmann A, Veyrac M, Le Moing V, Rispail P, et al. Pulmonary
cryptococcosis in a patient with Crohn’s disease treated with prednisone, azathioprine and
adalimumab: exposure to chicken manure as a source of contamination. J Crohns Colitis.
2013;7:e11–4. - Belda A, Hinojosa J, Serra B, Garcia L, Merino C, Belda A, et al. Systemic candidiasis and
infliximab therapy. Gastroenterol Hepatol. 2004;27:365–7.
R.M. MarchionifiBeery and J.R. Korzenik